Clinically observed prognostic improvements in cancer patients with a high level of TF-specific IgG Abs [17, 32–34] and encouraging experiments with TF-specific monoclonal antibodies (MAbs) [35, 36] indicate that the TF-specific innate and/or adaptive immune response is an important part of cancer immunosurveillance, and the TF antigen is a promising molecular target for cancer immunotherapy [14, 37–40]. Here, TF is linked to cancer.